Literature DB >> 11404539

Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy.

P M Tarwater1, J B Margolick, J Jin, J P Phair, R Detels, C Rinaldo, J Giorgi, A Muñoz.   

Abstract

We evaluated CD4 cell counts over a 3(1/2) year period following the initiation of potent antiretroviral therapy (ART) in the Multicenter AIDS Cohort Study. The study population included 314 HIV-infected gay men who provided CD4 cell counts for at least 2 years after the initiation of potent ART. Trends in CD4 cell counts and plasma HIV-RNA were analyzed by regression methods that incorporated the statistical dependencies of outcomes measured over time within individuals. Regardless of CD4 cell count at initiation of potent ART, CD4 cell counts increased significantly (p <.05) in the first 2 years after initiation. However, between 2 and 3(1/2) years after initiation, these counts neither increased nor decreased. The pattern of the proportion with plasma HIV-RNA <400 copies/ml was similar to CD4 cell count (i.e., increased significantly after initiation and plateau in the subsequent 1(1/2) years). The single most important predictor of the steady state CD4 cell count that was maintained between 2 and 3(1/2) years after initiation was the change in plasma HIV-RNA in the first year after initiation of potent ART.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11404539     DOI: 10.1097/00126334-200106010-00012

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  30 in total

1.  Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Authors:  Lisa P. Jacobson; John P. Phair; Traci E. Yamashita
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

2.  Update on the Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Authors:  Lisa P. Jacobson; John P. Phair; Traci E. Yamashita
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

3.  US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Authors:  Anita Brogan; Josephine Mauskopf; Sandra E Talbird; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Authors:  Karen Moeremans; Lieven Annemans; Mickael Löthgren; Gabriele Allegri; Veronique Wyffels; Lindsay Hemmet; Karin Caekelbergh; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Authors:  Karen Moeremans; Lindsay Hemmett; Jonas Hjelmgren; Gabriele Allegri; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

Authors:  Josephine Mauskopf; Anita Brogan; Silas Martin; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 7.  Virologic and immunologic response to highly active antiretroviral therapy.

Authors:  Lisa P Jacobson; John P Phair; Traci E Yamashita
Journal:  Curr HIV/AIDS Rep       Date:  2004-06       Impact factor: 5.071

8.  Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment.

Authors:  Colleen F Kelley; Christina M R Kitchen; Peter W Hunt; Benigno Rodriguez; Frederick M Hecht; Mari Kitahata; Heide M Crane; James Willig; Michael Mugavero; Michael Saag; Jeffrey N Martin; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2009-03-15       Impact factor: 9.079

9.  Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis.

Authors:  Xavier Anglaret; Callie A Scott; Rochelle P Walensky; Eric Ouattara; Elena Losina; Raoul Moh; Jessica E Becker; Lauren Uhler; Christine Danel; Eugene Messou; Serge Eholié; Kenneth A Freedberg
Journal:  Antivir Ther       Date:  2012-07-18

10.  The effect of HAART on HIV RNA trajectory among treatment-naïve men and women: a segmental Bernoulli/lognormal random effects model with left censoring.

Authors:  Haitao Chu; Stephen J Gange; Xiuhong Li; Donald R Hoover; Chenglong Liu; Joan S Chmiel; Lisa P Jacobson
Journal:  Epidemiology       Date:  2010-07       Impact factor: 4.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.